less than 0.1 mm mean difference (p <0.0001). The cuff size chosen was between 4 and 5.5 cm with 47% of the cuffs chosen being 4.5 cm. There was no significant difference in the measurements of circumference without a catheter, with a 12 or 16 French catheter in place (p<0.0001) suggesting that final cuff size was not influenced by the presence or absence of a urethral catheter.
INTRODUCTION AND OBJECTIVES: Artificial Urinary
Sphincter (AUS) insertion is the most effective treatment for moderate to severe incontinence in men. With over 3500 devices placed annually in the United States, a significant cost burden is associated with inpatient care. We sought to determine whether inpatient management after AUS insertion, our current local standard of care, is necessary with regards to pain control and immediate postoperative complications.
METHODS: In this IRB approved, retrospective review, AUS insertions between June 2013 and September 2017 were identified by CPT code 53445. Medical records were reviewed for patient demographics, medical and surgical history, length of stay, postoperative narcotic use, and immediate postoperative complications.
RESULTS: We identified 163 men who met inclusion criteria. The mean age and BMI were 69.3 þ 9.4 years and 29.6 þ 9.7 kg/m2, respectively. Twenty-three (14 %) patients were using chronic narcotic pain medication preoperatively, 33 (20 %) were on anticoagulation other than ASA-81 mg, and 51 (31 %) had diabetes (mean hemoglobin A1c 7.0 þ 1.5 %). Patient history included radical prostatectomy (RP) alone in 95 (58 %), radiation (XRT) alone in 15 (9 %), and RP and XRT in 40 (25 %). Twenty (12%) patients had a history of TURP or HoLEP, 14 of whom also had a history of RP and/or XRT. Sixteen (10 %) patients had a history of prior AUS.
All patients were discharged on the first postoperative day (POD 1) except for one patient discharged on POD 2. Two (1.2 %) patients experienced postoperative complications prior to discharge. One patient demonstrated altered mental status that resolved with conservative management (Clavien grade I) and the second displayed postoperative tachycardia requiring medical therapy (Clavien grade II). The 154 (94%) patients who required post-PACU narcotic pain medication used a median of 31.1 (IQR 15-45) morphine milligram equivalents (mme). The 82 (50%) patients who required post-PACU IV narcotic pain medication used a median of 4 (IQR 2-6) mme.
CONCLUSIONS: The vast majority of patients underwent uncomplicated AUS insertions with minimal post-PACU IV narcotic requirements. Virtually all were discharged on POD 1. Transitioning to outpatient AUS insertion appears reasonable and may have a meaningful impact on patient experience and total costs.
Source of Funding: None

PD37-10 ARTIFICIAL URINARY SPHINCTER REVISION WITH QUICK-CONNECTORSÒ VERSUS SUTURE-TIE CONNECTORS: DOES TECHNIQUE MAKE A DIFFERENCE?
Jack Andrews*, Brian Linder, Joseph Scales, Daniel Elliott, Rochester, MN INTRODUCTION AND OBJECTIVES: While artificial urinary sphincter placement remains the gold standard treatment option for men with stress urinary incontinence, roughly a quarter of men will undergo device revision for recurrent incontinence. For patients undergoing single component device revision the surgical dogma has been to use suture-tie connectors exclusively, as opposed to the Sutureless Quick-ConnectorsÒ (QC), which are routinely used in primary implantations. We sought to evaluate characteristics of artificial urinary sphincter mechanical failures and compare outcomes based on the use of either suture-tied connections or QuickConnectsÒ for single component revisions.
METHODS: A total of 1082 men with stress urinary incontinence underwent primary artificial urinary sphincter procedures from 1983 to 2011 at our institution. Of these, 125 experienced mechanical device malfunction, including 117 that underwent subsequent revision surgery at our institution. With regard to revisions, prior to 1996 all revision cases were performed with suture-tie connections and after this we used QC for revisions. Multiple clinical and surgical variables were evaluated for a potential association with repeat AUS surgery including the type of connector used. RESULTS: Of the 117 patients that underwent revision surgery for primary device malfunction, 46 were single component revisions. In these cases, the tubing connections were performed using suture-tie connectors in 34 (74%) cases and QC in 12 (26%) cases. The median follow-up after revision surgery was 24 months (IQR 7.2, 55.2) ( Table 1 ). There was no significant difference in 5-year device survival between suture-tie and QC (36% vs 61%; p[0.85) (Figure 1 ). There were no cases of device infection or repeat mechanical failure at the connector among revision cases utilizing QC, as compared to five device infections and four repeat mechanical failures among the suture-tie cohort.
INTRODUCTION AND OBJECTIVES: AMS implantation is a standard treatment for severe urinary stress incontinence (SUI). According to the literature, patients suffering from Parkinson's disease show adverse continence outcomes after prostate surgery and therefore constitute a challenging cohort for continence surgery. However, there is little known with respect to the results of AUS surgery in these patients. A prospective analysis of our AUS database aims to address this aspect with a focus on surgical and functional outcome METHODS: Since 2009, we prospectively collect data for all patients who undergo AMS 800 implantation due to SUI at our tertiary center. Further follow-up (FU), consisting of pad test, maximal urinary flow rate (Qmax), post void residual urine (PVR), radiography, and standardized questionnaire, is scheduled 6, 24 months and every two years thereafter. Every patient received an urodynamic measurement before AUS implantation. Only patients with normal voiding and storage function of the bladder were considered for AUS implantation. Patients with a history of a stroke or suffering from Parkinson's disease were grouped and compared to non-neurological patients. Primary and secondary endpoints of the study were complication and continence rates respectively. Objective continence was achieved if no safety pad was used per day. Social continence was defined as < 2 pads per day RESULTS: A total of 234 patients were available for analysis. There were 10 patients lost to FU. Median FU was 24 months (IQR 7-36). A total of 24 patients (10.1%) showed a history of a stroke or Parkinson's disease. Comparing these patients to those without a neurological history, significant differences with respect to continence rates are to be seen (p[0.04, p[0.02 and p[0. 093 for objective, subjective and social continence respectively). A significant difference concerning complications in terms of explantation rates was not observed (p[1) . A Kaplan-Meier analysis showed no significant difference regarding explantation free survival (log-rank [ 0.526) CONCLUSIONS: AUS implantation shows significantly worse continence rates for patients with a neurological history. This effect can be observed despite the fact that every patient showed normal bladder storage function in the pre-implantation urodynamic evaluation. This study shows that the AUS implantation seems to be a safe and viable treatment for patients with a history of neurological disease. However, they should be counseled for worse continence outcomes INTRODUCTION AND OBJECTIVES: Urethral atrophy has long been suggested as the leading cause of artificial urinary sphincter (AUS) revision. Since introduction of the 3.5 cm AUS cuff to the U.S. market in 2011, precise cuff sizing has been suggested to reduce revisions due to urethral atrophy. We evaluated a large series of reoperative AUS cases in an effort to determine reasons for revision surgery. We hypothesized that appropriate primary use of the 3.5 cm cuff prevents the need for subsequent revision due to urethral atrophy.
METHODS: We retrospectively reviewed our tertiary referral center database of male AUS procedures performed by a single surgeon from 2007-2018. Only AUS revision or replacement procedures were included for analysis. AUS cuff sizes and reasons for reoperation were recorded based on intraoperative findings and cystography. Patients with AUS cuff erosion or lacking follow up were excluded. Success was defined as having no subsequent revisions and continence of 1 pad per day at follow up.
RESULTS: Among 621 evaluable AUS cases, 153 were revisions or replacements. Of these, 113 met inclusion criteria with complete data (mean age 71.2 years, median follow up 9 months [range 1-107]). Urethral atrophy was cited as the cause of AUS failure in 7.96% (9/113) of cases overall, and almost never among those having 3.5 cm cuff placement (1/45, 2.2%). Among those with !4.0 cm cuffs, atrophy was the reason for revision in 8/68 (11.76%). Pressure regulating balloon (PRB) failure was the most frequently cited cause of failure (39/ 113, 34.5 %). Failure of unknown etiology (28/113, 24.8%) and cuffrelated failure (26/113, 23%) were the second and third most frequent causes of failure. Of cuff-related failures, cuff leaks (11/26, 42.3%) and need for proximal cuff relocation (8/26, 30.7%) were cited as most frequent reasons for revision. The overall success rate of these procedures was 54.0% (61/113). Success rates were markedly higher following total system replacements (36/52, 69.2%) compared to subtotal system replacements (22/60, 36.6%) [p<0.001].
CONCLUSIONS: Urethral atrophy is now a rare cause of AUS revision surgery in the current era of 3.5 cm cuff placement. Rather, PRB-related failure is now the leading cause of AUS failure overall. Total AUS system replacement results in better outcomes than subtotal system replacement.
